Hologic (NASDAQ:HOLX) Rating Lowered to Neutral at Mizuho

Hologic (NASDAQ:HOLX) was downgraded by analysts at Mizuho from an “outperform” rating to a “neutral” rating in a research report issued on Thursday, Marketbeat reports. They currently have a $78.00 price target on the medical equipment provider’s stock, up from their prior price target of $70.00. Mizuho’s price objective indicates a potential upside of 5.56% from the stock’s previous close.

Several other analysts have also weighed in on the stock. UBS Group lifted their price objective on shares of Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a research note on Thursday, July 31st. Royal Bank Of Canada upgraded shares of Hologic from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Hologic in a research note on Wednesday, October 8th. Evercore ISI set a $78.00 price objective on shares of Hologic and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Finally, Raymond James Financial lowered shares of Hologic from a “moderate buy” rating to a “hold” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $79.23.

Hologic Stock Down 0.1%

Shares of NASDAQ HOLX opened at $73.89 on Thursday. The company has a market capitalization of $16.43 billion, a P/E ratio of 30.66, a price-to-earnings-growth ratio of 2.54 and a beta of 0.63. Hologic has a 52-week low of $51.90 and a 52-week high of $84.39. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The company’s 50 day moving average price is $67.53 and its 200-day moving average price is $63.85.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities analysts forecast that Hologic will post 4.28 earnings per share for the current year.

Insider Buying and Selling at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Christiana Stamoulis sold 7,402 shares of the company’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the sale, the director owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. The trade was a 13.52% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.88% of the company’s stock.

Hedge Funds Weigh In On Hologic

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Chung Wu Investment Group LLC purchased a new position in shares of Hologic in the 2nd quarter worth about $26,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 273 shares during the last quarter. SJS Investment Consulting Inc. boosted its holdings in shares of Hologic by 341.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 362 shares during the last quarter. Loomis Sayles & Co. L P purchased a new position in shares of Hologic in the 2nd quarter worth about $33,000. Finally, Zions Bancorporation National Association UT purchased a new position in shares of Hologic in the 1st quarter worth about $34,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.